Athersys to Host Business Update Conference Call on August 9th
31 Juli 2023 - 7:38PM
Business Wire
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and
regenerative medicine company developing MultiStem® (invimestrocel)
for critical care indications, announced today it will host a
business update conference call on August 9, 2023, at 4:30 p.m.
Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen,
Chief Operating Officer, Kasey Rosado, Interim Chief Financial
Officer, and Willie Mays, Executive Vice President of Regenerative
Medicine and Head of Neuroscience, will provide an overview of the
Company’s recent clinical and operational progress and discuss
timing to conduct an interim analysis with MASTERS-2, a Phase 3
pivotal trial of MultiStem treatment in ischemic stroke.
Date
August 9, 2023
Time
4:30 p.m. (Eastern Time)
Live conference call registration
Call registration link
In lieu of a live question and answer session, management
encourages participants to submit questions in advance to
ir@athersys.com. A replay of the event will be available under the
Investors section on the Athersys website www.athersys.com.
About MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented
regenerative medicine product in clinical development that has
shown the ability to promote tissue repair and healing in a variety
of ways, such as through the production of therapeutic factors in
response to signals of inflammation and tissue damage. MultiStem
therapy’s potential for multidimensional therapeutic impact
distinguishes it from traditional biopharmaceutical therapies
focused on a single mechanism of benefit. The therapy represents a
unique "off-the-shelf" stem cell product that can be manufactured
in a scalable manner, may be stored for years in frozen form, and
is administered without tissue matching or the need for immune
suppression. Based upon its efficacy profile, its novel mechanisms
of action, and a favorable and consistent tolerability demonstrated
in clinical studies, we believe that MultiStem therapy could
provide a meaningful benefit to patients, including those suffering
from serious diseases and conditions with unmet medical need.
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, inflammatory and immune, and other
critical care indications and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. Investors and others should note that we may
post information about the Company on our website at
www.athersys.com and/or on our accounts on Twitter, Facebook,
LinkedIn or other social media platforms. It is possible that the
postings could include information deemed to be material
information. Therefore, we encourage investors, the media and
others interested in the Company to review the information we post
on our website at www.athersys.com and on our social media
accounts. Follow Athersys on Twitter at www.twitter.com/athersys.
Information that we may post about the Company on our website
and/or on our accounts on Twitter, Facebook, LinkedIn or other
social media platforms may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties. You should not place
undue reliance on forward-looking statements contained on our
website and/or on our accounts on Twitter, Facebook, LinkedIn or
other social media platforms, and we undertake no obligation to
publicly update forward-looking statements, whether as a result of
new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230731111218/en/
Athersys Ellen Gurley Manager of Corporate Communications
and Investor Relations ir@athersys.com LHA Investor
Relations Tirth T. Patel 212-201-6614
Athersys (NASDAQ:ATHX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024